KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBITDA data on record, last reported at $853.1 million in Q4 2025.

  • For Q4 2025, EBITDA changed 0.41% year-over-year to $853.1 million; the TTM value through Dec 2025 reached $4.6 billion, up 2.33%, while the annual FY2025 figure was $4.6 billion, 2.33% up from the prior year.
  • EBITDA reached $853.1 million in Q4 2025 per REGN's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, EBITDA topped out at $3.3 billion in Q2 2021 and bottomed at $725.7 million in Q1 2024.
  • Average EBITDA over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 255.37% in 2021, then tumbled 76.15% in 2022.
  • A 5-year view of EBITDA shows it stood at $1.8 billion in 2021, then plummeted by 33.23% to $1.2 billion in 2022, then increased by 1.79% to $1.3 billion in 2023, then tumbled by 32.33% to $849.6 million in 2024, then increased by 0.41% to $853.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $853.1 million in Q4 2025, $1.5 billion in Q3 2025, and $1.4 billion in Q2 2025.